The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain
Abstract
Chimeric receptors that include CD28 signaling in series with TCRζ in the same receptor have been demonstrated to activate prestimulated human primary T cells more efficiently than a receptor providing TCRζ signaling alone. We examined whether this type of receptor can also activate resting human primary T cells, and whether molecules other than CD28 could be included in a single chimeric receptor in series with TCRζ to mediate the activation of resting human primary T cells. Human CD33-specific chimeric receptors were generated with CD28, inducible costimulator, CD134, or CD137 signaling regions in series with TCRζ signaling region and transfected by electroporation into resting human primary T cells. Their ability to mediate Ag-specific activation was analyzed in comparison with a receptor providing TCRζ signaling alone. Inclusion of any of the costimulatory signaling regions in series with TCRζ enhanced the level of specific Ag-induced IL-2, IFN-γ, TNF-α, and GM-CSF cytokine production and enabled resting primary T cells to survive and proliferate in response to Ag in the absence of any exogenous factors. Inclusion of CD28, inducible costimulator, or CD134 enhanced TCRζ-mediated, Ag-specific target cell lysis. Chimeric receptors providing B7 and TNFR family costimulatory signals in series with TCRζ in the same receptor can confer self-sufficient clonal expansion and enhanced effector function to resting human T cells. This type of chimeric receptor may now be used to discover the most potent combination of costimulatory signals that will improve current immunotherapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,692
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,559
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
ICOS co-stimulatory receptor is essential for T-cell activation and function
Dong, C., Juedes, A. E., Temann, U.-A., Shresta, S., Allison, J. P., Ruddle, N. H., & Flavell, R. A. (2001) · Nature · doi:10.1038/35051100 · Cited by 936
T-cell regulation by CD28 and CTLA-4
Alegre, M.-L., Frauwirth, K. A., & Thompson, C. B. (2001) · Nature Reviews Immunology · doi:10.1038/35105024 · Cited by 914
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Carreno, B. M., & Collins, M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091101.091806 · Cited by 896
Miller, D. G., Adam, M. A., & Miller, A. D. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.8.4239 · Cited by 893
Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.47 · Cited by 804
Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system.
Aruffo, A., & Seed, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8573 · Cited by 784
Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency
Grimbacher, B., Hutloff, A., Schlesier, M., Glocker, E., Warnatz, K., Dräger, R., Eibel, H., Fischer, B., Schäffer, A. A., Mages, H. W., et al. (2003) · Nature Immunology · doi:10.1038/ni902 · Cited by 733
ICOS is essential for effective T-helper-cell responses
Tafuri, A., Shahinian, A., Bladt, F., Yoshinaga, S. K., Jordana, M., Wakeham, A., Boucher, L.-M., Bouchard, D., Chan, V. S. F., Duncan, G., et al. (2001) · Nature · doi:10.1038/35051113 · Cited by 675
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
ICOS is critical for CD40-mediated antibody class switching
McAdam, A. J., Greenwald, R. J., Levin, M. A., Chernova, T., Malenkovich, N., Ling, V., Freeman, G. J., & Sharpe, A. H. (2001) · Nature · doi:10.1038/35051107 · Cited by 647
OX40 Promotes Bcl-xL and Bcl-2 Expression and Is Essential for Long-Term Survival of CD4 T Cells
Rogers, P. R., Song, J., Gramaglia, I., Killeen, N., & Croft, M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00191-1 · Cited by 646
June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T., & Thompson, C. B. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.12.4472 · Cited by 566
CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells
Jenkins, M. K., Taylor, P. S., Norton, S. D., & Urdahl, K. B. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2461 · Cited by 562
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Self-citationTargeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses
Gramaglia, I., Weinberg, A. D., Lemon, M., & Croft, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6510 · Cited by 527
The CD28-Related Molecule ICOS Is Required for Effective T Cell–Dependent Immune Responses
Coyle, A. J., Lehar, S., Lloyd, C., Tian, J., Delaney, T., Manning, S., Nguyen, T., Burwell, T., Schneider, H., Gonzalo, J. A., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00011-x · Cited by 520
Tan, P., Anasetti, C., Hansen, J. A., Melrose, J., Brunvand, M., Bradshaw, J., Ledbetter, J. A., & Linsley, P. S. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.1.165 · Cited by 461
Inoue, J.-I., Ishida, T., Tsukamoto, N., Kobayashi, N., Naito, A., Azuma, S., & Yamamoto, T. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4733 · Cited by 447
McAdam, A. J., Chang, T. T., Lumelsky, A. E., Greenfield, E. A., Boussiotis, V. A., Duke-Cohan, J. S., Chernova, T., Malenkovich, N., Jabs, C., Kuchroo, V. K., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5035 · Cited by 440
Mitsuyasu, R. T., Anton, P. A., Deeks, S. G., Scadden, D. T., Connick, E., Downs, M. T., Bakker, A., Roberts, M. R., June, C. H., Jalali, S., et al. (2000) · Blood · doi:10.1182/blood.v96.3.785 · Cited by 425
Gramaglia, I., Jember, A., Pippig, S. D., Weinberg, A. D., Killeen, N., & Croft, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3043 · Cited by 409
Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling
Pagès, F., Ragueneau, M., Rottapel, R., Truneh, A., Nunes, J., Imbert, J., & Olive, D. (1994) · Nature · doi:10.1038/369327a0 · Cited by 398
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 387
Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal
Takahashi, C., Mittler, R. S., & Vella, A. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5037 · Cited by 379
Krause, A., Guo, H.-F., Latouche, J.-B., Tan, C., Cheung, N.-K. V., & Sadelain, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.619 · Cited by 365
CD28, CTLA‐4 and their ligands: who does what and to whom?
Sansom, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00121.x · Cited by 362
Arch, R. H., & Thompson, C. B. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.558 · Cited by 356
Flynn, S., Toellner, K.-M., Raykundalia, C., Goodall, M., & Lane, P. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.297 · Cited by 351
T cell co-stimulatory molecules other than CD28
Watts, T. H., & DeBenedettet, M. A. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)80046-6 · Cited by 341
CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
Saoulli, K., Lee, S. Y., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N., DeBenedette, M. A., Mak, T. W., Choi, Y., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1849 · Cited by 322
Functional Responses and Costimulator Dependence of Memory CD4+ T Cells
London, C. A., Lodge, M. P., & Abbas, A. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.265 · Cited by 314
Hombach, A., Wieczarkowiecz, A., Marquardt, T., Heuser, C., Usai, L., Pohl, C., Seliger, B., & Abken, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6123 · Cited by 299
Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes.
Brocker, T., & Karjalainen, K. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1653 · Cited by 296
Prasad, K. V., Cai, Y. C., Raab, M., Duckworth, B., Cantley, L., Shoelson, S. E., & Rudd, C. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2834 · Cited by 295
ICOS is critical for T helper cell–mediated lung mucosal inflammatory responses
Gonzalo, J. A., Tian, J., Delaney, T., Corcoran, J., Rottman, J. B., Lora, J., Al-garawi, A., Kroczek, R., Gutierrez-Ramos, J. C., & Coyle, A. J. (2001) · Nature Immunology · doi:10.1038/89739 · Cited by 279
Molecular Cloning of the Zeta Chain of the T Cell Antigen Receptor
Weissman, A. M., Baniyash, M., Hou, D., Samelson, L. E., Burgess, W. H., & Klausner, R. D. (1988) · Science · doi:10.1126/science.3278377 · Cited by 278
Ohshima, Y., Yang, L.-P., Uchiyama, T., Tanaka, Y., Baum, P., Sergerie, M., Hermann, P., & Delespesse, G. (1998) · Blood · doi:10.1182/blood.v92.9.3338 · Cited by 268
Tan, J. T., Whitmire, J. K., Ahmed, R., Pearson, T. C., & Larsen, C. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4859 · Cited by 259
Hurtado, J. C., Kim, Y. J., & Kwon, B. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2600 · Cited by 257
Andrews, R., Torok-Storb, B., & Bernstein, I. (1983) · Blood · doi:10.1182/blood.v62.1.124.124 · Cited by 257
Moslecular and biological characterization of human 4‐1BB and its ligands
Alderson, M. R., Smith, C. A., Tough, T. W., Davis‐Smith, T., Armitage, R. J., Falk, B., Roux, E., Baker, E., Sutherland, G. R., Din, W. S., et al. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240943 · Cited by 244
WALKER, R. E., Bechtel, C. M., Natarajan, V., Baseler, M., Hege, K. M., Metcalf, J. A., Stevens, R. A., Hazen, A., Blaese, R. M., Chen, C. C., et al. (2000) · PubMed · doi:10.1182/blood.v96.2.467 · Cited by 222
Maxwell, J. R., Weinberg, A., Prell, R. A., & Vella, A. T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.107 · Cited by 219
Lucas, P. J., Negishi, I., Nakayama, K., Fields, L. E., & Loh, D. Y. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.11.5757 · Cited by 218
Roberts, M., Qin, L., Zhang, D., Smith, D., Tran, A., Dull, T., Groopman, J., Capon, D., Byrn, R., & Finer, M. (1994) · Blood · doi:10.1182/blood.v84.9.2878.2878 · Cited by 211
Wen, T., Bukczynski, J., & Watts, T. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4897 · Cited by 207
Wills, M. R., Okecha, G., Weekes, M. P., Gandhi, M. K., Sissons, P. J. G., & Carmichael, A. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5455 · Cited by 207
Kawamata, S., Hori, T., Imura, A., Takaori-Kondo, A., & Uchiyama, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5808 · Cited by 200
Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., & Darcy, P. K. (2002) · Blood · doi:10.1182/blood-2002-04-1041 · Cited by 197
CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response
Radvanyi, L. G., Shi, Y., Vaziri, H., Sharma, A., Dhala, R., Mills, G. B., & Miller, R. G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.5.1788 · Cited by 194
Brocker, T. (2000) · Blood · doi:10.1182/blood.v96.5.1999 · Cited by 181
Induction, binding specificity and function of human ICOS
Beier, K. C., Hutloff, A., Dittrich, A., Heuck, C. J., Rauch, A. M., Büchner, K., Ludewig, B., Ochs, H. D., Mages, H. W., & Kroczek, R. A. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200012)30:12<3707::aid-immu3707>3.0.co;2-q · Cited by 180
Human 4-1BB (CD137) Signals Are Mediated by TRAF2 and Activate Nuclear Factor-κB
Jang, I. K., Lee, Z. H., Kim, Y. J., Kim, S. H., & Kwon, B. S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.8016 · Cited by 176
Functional expression of chimeric receptor genes in human T cells
Eshhar, Z., Waks, T., Bendavid, A., & Schindler, D. G. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00343-4 · Cited by 158
Dunne, P. J., Faint, J. M., Gudgeon, N. H., Fletcher, J. M., Plunkett, F. J., Soares, M. V. D., Hislop, A. D., Annels, N. E., Rickinson, A. B., Salmon, M., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0160 · Cited by 144
Self-citationICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement
Riley, J. L., Blair, P. J., Musser, J. T., Abe, R., Tezuka, K., Tsuji, T., & June, C. H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4943 · Cited by 144
Álvarez‐Vallina, L., & Hawkins, R. E. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261006 · Cited by 125
The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen
Latza, U., Dürkop, H., Schnittger, S., Ringeling, J., Eitelbach, F., Hummel, M., Fonatsch, C., & Stein, H. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240329 · Cited by 122
Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., & Darcy, P. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5780 · Cited by 107
The T-body approach: potential for cancer immunotherapy
Eshhar, Z., Bach, N., Fitzer‐Attas, C. J., Grosse, G., Lustgarten, J., Waks, T., & Schindler, D. G. (1996) · Springer Seminars in Immunopathology · doi:10.1007/bf00820666 · Cited by 103
Han, T.-H., Lamph, W. W., & Prywes, R. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.10.4472 · Cited by 99
Geiger, T. L., Nguyen, P., Leitenberg, D., & Flavell, R. A. (2001) · Blood · doi:10.1182/blood.v98.8.2364 · Cited by 90
Endowing T cells with antibody specificity using chimeric T cell receptors
Gross, G., & Eshhar, Z. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.15.1464371 · Cited by 87
Gilham, D. E., O'Neil, A., Hughes, C., Guest, R. D., Kirillova, N., Lehane, M., & Hawkins, R. E. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00002 · Cited by 67
The complexity of the B7-CD28/CTLA-4 costimulatory pathway
Schweitzer, A., & Sharpe, A. H. (1998) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8857-8_6 · Cited by 21
T-lymphocyte coactivator molecules
Salazar‐Fontana, L. I., & Bierer, B. E. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200101000-00002 · Cited by 20
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Metadata
- Authors
- Finney, H. M., Akbar, A. N., & Lawson, A. D. G.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01-01
- Volume
- 172
- Issue
- 1
- Pages
- 104-113
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2165580475
- Cited by
- 467
- References
- 77
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.